The 2025 AHS guidelines mandate offering IV prochlorperazine and greater occipital nerve blocks to eligible adults with acute migraine in the emergency department, while strongly advising against IV hydromorphone.
The American Headache Society (AHS) has released its 2025 evidence-based guideline update for acute adult migraine care in the emergency department (ED). Expanding on the 2016 framework, this systematic review and meta-analysis synthesized 26 new randomized controlled trials (RCTs) evaluating 20 injectable and procedural therapies to establish a definitive treatment hierarchy.
The literature search covered MEDLINE, Embase, Cochrane, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. Study quality was assessed via American Academy of Neurology (AAN) criteria.
Summary of Recommendations
Practice Impact
This guideline overhaul modernizes emergency protocols by replacing routine opioids and acetaminophen with targeted cranial nerve blocks, nonsteroidal anti-inflammatory drugs (NSAIDs), and dopamine antagonists for rapid, evidence-grounded relief.
Headache
2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
Jennifer Robblee et al.
Comments (0)